Literature DB >> 29263458

Creatine kinase-MB and red cell distribution width as predictors of contrast-induced nephropathy after percutaneous coronary intervention in acute myocardial infarction.

Katarzyna Zbierska-Rubinkiewicz1, Oksana Trębacz, Marek Tomala, Mateusz Rubinkiewicz, Iwona Chrzan, Andrzej Gackowski.   

Abstract

INTRODUCTION: Contrast-induced nephropathy (CIN) is acute kidney injury (AKI), caused by administration of iodinated contrast media. The reported risk factors of CIN are: pre-existing renal dysfunction, admission anemia, diabetic nephropathy, old age, dehydration, high volume and osmolarity of administered contrast media. Patients with acute myocardial infarction (AMI) have threefold higher risk of developing CIN. The aim of the study was to identify risk factors of CIN among patients who underwent percutaneous coronary intervention (PCI) due to AMI.
METHODS: This retrospective single-centre study included 257 patients (mean age, 69.19 ± 1.4 years; men 66.15%) undergoing PCI for AMI between January 2012 and January 2013. Demographic data, type and location of MI, co-morbidities and laboratory results were analysed.
RESULTS: CIN was found in 50 out of 257 patients (19.5%). Patients who developed CIN were older (p = 0.001), more commonly had chronic kidney disease (p = 0.01) and lower LVEF (p = 0.01). Baseline Red Cell Distribution Width (RDW) was significantly higher in the CIN group (14.85 ± 4.6 vs. 13.62 ± 1.3, p = 0.001). CK-MB levels on admission were significantly higher in the CIN group compared to the non- CIN group (95.6 ± 129.9 vs. 47.03 ± 61.3, p = 0.001). Multivariate model including "classical" CIN risk actors revealed that only baseline CK-MB level (p = 0.001), age >75 years (p = 0.001) and baseline RDW (p = 0.03) were independent predictors for the development of CIN.
CONCLUSION: In conclusion, increased CK-MB on admission as a surrogate of time of ischemia, and increased RDW levels on admission as a marker of chronic in ammation are independently associated with higher risk of CIN among patients treated with primary PCI.

Entities:  

Keywords:  acute renal disease; contrast agents; coronary angiography; primary PCI

Mesh:

Substances:

Year:  2017        PMID: 29263458

Source DB:  PubMed          Journal:  Folia Med Cracov        ISSN: 0015-5616


  5 in total

1.  Red blood cell distribution width predicts long-term mortality in critically ill patients with acute kidney injury: a retrospective database study.

Authors:  Linpei Jia; Shijun Cui; Jingyan Yang; Qiang Jia; Lixiao Hao; Rufu Jia; Hongliang Zhang
Journal:  Sci Rep       Date:  2020-03-12       Impact factor: 4.379

2.  MIRKB: a myocardial infarction risk knowledge base.

Authors:  Chaoying Zhan; Manhong Shi; Rongrong Wu; Hongxin He; Xingyun Liu; Bairong Shen
Journal:  Database (Oxford)       Date:  2019-01-01       Impact factor: 3.451

Review 3.  From Classic to Modern Prognostic Biomarkers in Patients with Acute Myocardial Infarction.

Authors:  Cristian Stătescu; Larisa Anghel; Bogdan-Sorin Tudurachi; Andreea Leonte; Laura-Cătălina Benchea; Radu-Andy Sascău
Journal:  Int J Mol Sci       Date:  2022-08-15       Impact factor: 6.208

4.  Prognostic Impact of Red Cell Distribution Width on the Development of Contrast-Induced Nephropathy, Major Adverse Cardiac Events, and Mortality in Coronary Artery Disease Patients Undergoing Percutaneous Coronary Intervention.

Authors:  Azka Latif; Muhammad Junaid Ahsan; Noman Lateef; Vikas Kapoor; Hafiz Muhammad Fazeel; Faryal Razzaq; Ahmad Iftikhar; Muhammad Zubair Ashfaq; Faiz Anwer; Mohsin Mirza; Amjad Kabach
Journal:  Curr Cardiol Rev       Date:  2021

5.  Predictive value of creatine kinase MB for contrast-induced acute kidney injury among myocardial infarction patients.

Authors:  Wen Wei; Lingyu Zhang; Yunhan Zhang; Ronghui Tang; Miao Zhao; Zhidong Huang; Jin Liu; Danyuan Xu; Yibo He; Bo Wang; Haozhang Huang; Qiang Li; Mengfei Lin; Yong Liu; Kaihong Chen; Shiqun Chen
Journal:  BMC Cardiovasc Disord       Date:  2021-07-13       Impact factor: 2.298

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.